# ARCHER (NCT05950139)

> Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05950139
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Conditions: NSCLC Stage IV; ALK Fusion Protein Expression
- Interventions: Peptide vaccine
- Enrollment: 12
- Primary outcome: Incidence of treatment-related adverse events
- Primary outcome: Vaccine-specific immune response

## Commentary we found

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=archer-nct05950139